Feasibility of gastric endoscopic submucosal dissection with continuous low-dose aspirin for patients receiving dual antiplatelet therapy

Table 3 Comparison of therapeutic outcomes among patients receiving low-dose aspirin in the continuous low-dose aspirin group and the discontinuous low-dose aspirin group

	Continuous LDA (n = 95)	Discontinuous LDA (n = 59)	P value
Pathological findings, n (%)1
Differentiated	94 (98.9)	58 (98.3)	> 0.99
Undifferentiated	1 (1.1)	1 (1.7)
Depth of invasion, n (%)
Mucosa	80 (84.2)	52 (88.1)	0.637
Submucosa	15 (15.8)	7 (11.9)
Specimen size, median (IQR), mm	30 (25-39)	33 (25-41.5)	0.944
Complete resection, n (%)	91 (95.8)	57 (96.6)	> 0.99
Curative resection, n (%)	85 (89.5)	54 (91.5)	0.785
Postoperative bleeding, n (%)	15 (15.8)	5 (8.5)	0.225

¹Differentiated, adenoma/well or moderately differentiated adenocarcinoma/papillary adenocarcinoma; undifferentiated, signet-ring cell carcinoma/poorly differentiated adenocarcinoma/mucinous adenocarcinoma. IQR: Interquartile range; LDA: Low-dose aspirin.